These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28095868)

  • 21. Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.
    Harrison BT; Nakhlis F; Dillon DA; Soong TR; Garcia EP; Schnitt SJ; King TA
    Mod Pathol; 2020 Jul; 33(7):1287-1297. PubMed ID: 31932682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline CDH1 mutations in bilateral lobular carcinoma in situ.
    Petridis C; Shinomiya I; Kohut K; Gorman P; Caneppele M; Shah V; Troy M; Pinder SE; Hanby A; Tomlinson I; Trembath RC; Roylance R; Simpson MA; Sawyer EJ
    Br J Cancer; 2014 Feb; 110(4):1053-7. PubMed ID: 24366306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity.
    Soong TR; Dillon DA; Rice-Stitt TL; Wieczorek TJ; Baker GM; Darvishian F; Collins LC; Lester SC; Schnitt SJ; Harrison BT
    Mod Pathol; 2022 Oct; 35(10):1370-1382. PubMed ID: 35477749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular drivers of lobular carcinoma in situ.
    Logan GJ; Dabbs DJ; Lucas PC; Jankowitz RC; Brown DD; Clark BZ; Oesterreich S; McAuliffe PF
    Breast Cancer Res; 2015 Jun; 17():76. PubMed ID: 26041550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
    Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
    Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.
    De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA
    Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.
    Rieger-Christ KM; Pezza JA; Dugan JM; Braasch JW; Hughes KS; Summerhayes IC
    Mol Pathol; 2001 Apr; 54(2):91-7. PubMed ID: 11322170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma From a Single Academic Center.
    Shamir ER; Chen YY; Chu T; Pekmezci M; Rabban JT; Krings G
    Am J Surg Pathol; 2019 Mar; 43(3):399-408. PubMed ID: 30489319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.
    Vos CB; Cleton-Jansen AM; Berx G; de Leeuw WJ; ter Haar NT; van Roy F; Cornelisse CJ; Peterse JL; van de Vijver MJ
    Br J Cancer; 1997; 76(9):1131-3. PubMed ID: 9365159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
    Davis AA; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Hensing WL; Bucheit L; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Gradishar WJ; Behdad A; Ma CX; Bardia A; Cristofanilli M
    EBioMedicine; 2022 Dec; 86():104316. PubMed ID: 36332363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience.
    Hoffman DI; Zhang PJ; Tchou J
    Surg Oncol; 2019 Mar; 28():190-194. PubMed ID: 30851899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature.
    Foschini MP; Miglio R; Fiore R; Baldovini C; Castellano I; Callagy G; Bianchi S; Kaya H; Amendoeira I; Querzoli P; Poli F; Scatena C; Cordoba A; Pietribiasi F; Kovács A; Faistova H; Cserni G; Quinn C
    Eur J Surg Oncol; 2019 Dec; 45(12):2279-2286. PubMed ID: 31301938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
    Renshaw AA; Gould EW
    Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity.
    Zhong E; Solomon JP; Cheng E; Baum J; Song W; Hoda SA
    Am J Surg Pathol; 2020 Aug; 44(8):1092-1103. PubMed ID: 32317606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
    Ang DC; Warrick AL; Shilling A; Beadling C; Corless CL; Troxell ML
    Mod Pathol; 2014 May; 27(5):740-50. PubMed ID: 24186142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.
    Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B
    J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
    Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
    BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution Retrospective Study.
    Harinath L; Villatoro TM; Clark BZ; Fine JL; Yu J; Carter GJ; Diego E; McAuliffe PF; Mai P; Lu A; Zuley M; Berg WA; Bhargava R
    Mod Pathol; 2024 Apr; 37(4):100462. PubMed ID: 38428736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.